These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28982740)

  • 21. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
    Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.
    Jairath V; Peyrin-Biroulet L; Zou G; Mosli M; Vande Casteele N; Pai RK; Valasek MA; Marchal-Bressenot A; Stitt LW; Shackelton LM; Khanna R; D'Haens GR; Sandborn WJ; Olson A; Feagan BG; Pai RK
    Gut; 2019 Jul; 68(7):1162-1168. PubMed ID: 30076171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
    Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
    Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.
    Feagan BG; Schreiber S; Wolf DC; Axler JL; Kaviya A; James A; Curtis RI; Geransar P; Stallmach A; Ehehalt R; Bokemeyer B; Khalid JM; O'Byrne S
    Inflamm Bowel Dis; 2019 May; 25(6):1028-1035. PubMed ID: 30365009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients.
    Pagnini C; Siakavellas SI; Bamias G
    Gastroenterol Res Pract; 2018; 2018():6317057. PubMed ID: 30116266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-integrin therapy for inflammatory bowel disease.
    Park SC; Jeen YT
    World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
    Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Bamias G; Dulai PS; Boland BS; Sandborn WJ; Patel DR; Rivera-Nieves J
    Inflamm Bowel Dis; 2019 Jan; 25(2):270-282. PubMed ID: 30165490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
    D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
    Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
    Ng SC; Shi HY; Hamidi N; Underwood FE; Tang W; Benchimol EI; Panaccione R; Ghosh S; Wu JCY; Chan FKL; Sung JJY; Kaplan GG
    Lancet; 2017 Dec; 390(10114):2769-2778. PubMed ID: 29050646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action of vedolizumab: do we really understand it?
    Rogler G
    Gut; 2019 Jan; 68(1):4-5. PubMed ID: 30077996
    [No Abstract]   [Full Text] [Related]  

  • 32. Review article: novel oral-targeted therapies in inflammatory bowel disease.
    White JR; Phillips F; Monaghan T; Fateen W; Samuel S; Ghosh S; Moran GW
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1610-1622. PubMed ID: 29672874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α
    Li H; Huang SY; Shi FH; Gu ZC; Zhang SG; Wei JF
    Expert Opin Ther Pat; 2018 Dec; 28(12):903-917. PubMed ID: 30444683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort.
    Park SH; Aniwan S; Scott Harmsen W; Tremaine WJ; Lightner AL; Faubion WA; Loftus EV
    Inflamm Bowel Dis; 2019 May; 25(6):1054-1060. PubMed ID: 30346531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology.
    Weizman AV; Nguyen GC; Seow CH; Targownik L; Murthy SK; Boland K; Afzal NM; Khanna R; Jones J; Afif W; Halder S; Reinglas J; Fowler S; Huang V; Kaplan GG; Melmed GY
    Inflamm Bowel Dis; 2019 Jan; 25(2):328-335. PubMed ID: 30346529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Panés J; Salas A
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Filgotinib for the treatment of Crohn's disease.
    Labetoulle R; Paul S; Roblin X
    Expert Opin Investig Drugs; 2018 Mar; 27(3):295-300. PubMed ID: 29448862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
    Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence, risk factors, and prognostic significance of masked hypertension in diabetic patients.
    Zhao H; Zeng F; Wang X; Wang L
    Medicine (Baltimore); 2017 Oct; 96(43):e8363. PubMed ID: 29069022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower blood pressure and smaller pulse pressure in sleeping pill users: A large-scale cross-sectional analysis.
    Sasaki N; Fujiwara S; Ozono R; Yamashita H; Kihara Y
    Medicine (Baltimore); 2017 Oct; 96(42):e8272. PubMed ID: 29049222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.